Partially hydrolyzed guar gum alleviates hepatic steatosis and alters specific gut microbiota in a murine liver injury model

Emerging role of regulated cell death in intestinal failure-associated liver disease

Intestinal failure-associated liver disease (IFALD) is a common complication of long-term parenteral nutrition that is associated with significant morbidity and mortality. It is mainly characterized by cholestasis in children and steatohepatitis in adults. Unfortunately, there is no effective approach to prevent or reverse the disease. Regulated cell death (RCD) represents a fundamental biological paradigm that determines the outcome of a variety of liver diseases. Nowadays cell death is reclassified into several types, based on the mechanisms and morphological phenotypes. Emerging evidence has linked different modes of RCD, such as apoptosis, necroptosis, ferroptosis, and pyroptosis to the pathogenesis of liver diseases. Recent studies have shown that different modes of RCD are present in animal models and patients with IFALD. Understanding the pathogenic roles of cell death may help uncover the underlying mechanisms and develop novel therapeutic strategies in IFALD. In this review, we discuss the current knowledge on how RCD may link to the pathogenesis of IFALD. We highlight examples of cell death-targeted interventions aiming to attenuate the disease, and provide perspectives for future basic and translational research in the field.

Guar gum improves growth performance, intestinal microbiota homeostasis, and hepatic lipid metabolism in juvenile largemouth bass (Micropterus salmoides) fed high-fat diets

The study aimed to investigate the effects of guar gum on the growth performance, gut microbiota composition, and hepatic lipid metabolism of largemouth bass (Micropterus salmoides) fed high-fat diets. Experimental fish were fed a normal-fat diet (Control), high-fat diet (HF), or HF diets supplemented with 0.3 %, 1 %, and 3 % guar gum (GG0.3, GG1, and GG3, respectively) for eight weeks. The results showed that HF significantly decreased fish growth performance, increased hepatic lipid accumulation, upregulated the expression of sterol regulatory element binding proteins 1 (SREBP1), and downregulated the expression of liver X receptor alpha (LXRα), cytochrome P450 7A1 (CYP7A1), and CYP8B1, compared to Control. However, these problems of high-fat diets were significantly alleviated by GG 0.3. The intestinal microbial communities of the GG0.3 and Control were similar but distinctly different from that of the HF group. Compared to HF, GG0.3 significantly increased the relative abundances of Firmicutes and Lactococcus and decreased the relative abundance of Tenericutes, Mesomycoplasma, and Phenylobacterium. In addition, the GG0.3 and GG1 treatments significantly enhanced the bile salt hydrolase (BSH) activity in the digesta compared to HF. In conclusion, 0.3 % guar gum supplementation can improve growth performance, intestinal health, and hepatic lipid metabolism in fish fed high-fat diets.